Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis

AI Briefing

• – Bayer announces positive topline results from Phase III REVEAL study for investigational PET/CT radiotracer I 124 evuzamitide
• – Study met primary endpoints of sensitivity and specificity for diagnosis of cardiac amyloidosis
• – Positive findings support potential therapeutic application of I 124 evuzamitide